PDE / ADE · OEL / OEB

Home→PDE/ADE · OEL/OEB Profiles → Prajmalium→

Prajmalium PDE report and OEL report profile

Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.

CAS Registry Number
35080-11-6
Molecular formula
C23H33N2O2+
Molecular weight
369.5 g/mol
Drug class
Class Ia antiarrhythmiccardiac fast sodium-channel blocker
Mechanism of action
Blocks fast voltage-gated sodium channels in cardiac myocytes, slowing phase-0 depolarisation and conduction velocity. Class Ia activity also prolongs action-potential duration and effective refractory period through effects on repolarising potassium currents.
Indications / reported uses
  • Historically used for treatment of selected supraventricular and ventricular arrhythmias in countries where prajmalium remains authorised; availability and clinical role are jurisdiction-specific.

Sources: https://pubchem.ncbi.nlm.nih.gov/#query=prajmalium · https://www.ncbi.nlm.nih.gov/mesh/?term=prajmalium · FDA product information

View request basketPrefer email? info@toxwriter.com
PDE / ADE derivationOEL derivationOEB / OHC banding
Assessment scope

PDE/ADE and OEL/OEB assessment

ToxWriter provides project-specific support for Prajmalium PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Prajmalium Permitted Daily Exposure (PDE) report (the Prajmalium PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Prajmalium Occupational Exposure Limit (OEL) report (the Prajmalium OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.

Assessment may cover

  • PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
  • OEL derivation considering relevant hazards, exposure route, duration and workplace conditions.
  • OEB/OHC banding where requested and supported by the evidence; an exposure band is not a numerical OEL.
  • Review of substance identity, evidence quality, uncertainty and data gaps.
PDE/ADE, OEL & OEB/OHC regulatory framework

The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.